专题：Lymphoma Diagnosis and Treatment

This cluster of papers focuses on the classification, molecular profiling, genetic pathogenesis, and treatment strategies for various types of lymphoid neoplasms, including Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma. It also explores the use of PET imaging, rituximab therapy, and gene expression profiling to predict survival and guide treatment decisions.
最新文献
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

article Full Text OpenAlex

BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies

review Full Text OpenAlex

Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity

article Full Text OpenAlex

Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know

review Full Text OpenAlex

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

article Full Text OpenAlex

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

article Full Text OpenAlex

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

article Full Text OpenAlex

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

article Full Text OpenAlex

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

article Full Text OpenAlex

The role of stem cell transplant (auto and allo) in PTCL and CTCL

review Full Text OpenAlex

近5年高被引文献
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

review Full Text OpenAlex 3136 FWCI649.38936651

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

article Full Text OpenAlex 2261 FWCI507.48103847

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

article Full Text OpenAlex 1322 FWCI102.73486371

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

article Full Text OpenAlex 1268 FWCI261.57975759

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

review Full Text OpenAlex 1137 FWCI198.73297801

Diffuse Large B-Cell Lymphoma

review Full Text OpenAlex 946 FWCI126.2197953

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

review Full Text OpenAlex 923 FWCI140.6278866

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

article Full Text OpenAlex 703 FWCI157.63349071

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

article Full Text OpenAlex 675 FWCI83.40840274

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

article Full Text OpenAlex 663 FWCI98.61462819